AG-013736

DRUG13 trials

Sponsors

Pfizer, University of Wisconsin, Madison, Arog Pharmaceuticals, Inc., National Taiwan University Hospital

Conditions

Advanced Solid TumorsCarcinoma, Non-Small-Cell Lung (NSCLC)Carcinoma, Pancreatic DuctalCarcinoma, Renal CellHealthy VolunteerHealthy VolunteersHepatic InsufficiencyHepatocellular Carcinoma

Phase 1

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

CompletedNCT00692341

PfizerHepatic Insufficiency

Start: 2008-05-31End: 2008-10-31Updated: 2012-04-11

Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies

CompletedNCT00859118

University of Wisconsin, MadisonNeoplasms

Start: 2009-02-28End: 2014-12-31Updated: 2019-11-19

A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers

CompletedNCT00905814

PfizerHealthy Volunteers

Start: 2009-07-31End: 2009-09-30Updated: 2009-11-16

Food Effect Study Of AG-013736 In Healthy Volunteers

CompletedNCT00918632

PfizerHealthy Volunteers

Start: 2009-06-30End: 2009-07-31Updated: 2009-08-04

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

CompletedNCT00949624

Arog Pharmaceuticals, Inc.Advanced Solid Tumors

Start: 2005-12-31End: 2008-06-30Updated: 2012-01-19

A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers

CompletedNCT01020136

PfizerHealthy Volunteer

Start: 2010-01-31End: 2010-02-28Updated: 2010-04-22

First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

CompletedNCT01469052

PfizerAdvanced Solid Tumors

Start: 2002-11-30End: 2004-08-31Updated: 2012-03-26

Phase 2

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

CompletedNCT00219557

PfizerPancreatic Neoplasms

Start: 2005-07-05End: 2008-03-14Updated: 2019-05-14

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

CompletedNCT00389441

PfizerThyroid Neoplasms

Start: 2006-12-31End: 2012-09-30Updated: 2013-11-25

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

CompletedNCT00569946

PfizerCarcinoma, Renal Cell

Start: 2007-12-12End: 2012-10-30Updated: 2019-06-05

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

CompletedNCT00735904

PfizerCarcinoma, Non-Small-Cell Lung (NSCLC)

Start: 2008-12-31End: 2011-11-30Updated: 2013-01-03

Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma

CompletedNCT01273662

National Taiwan University HospitalHepatocellular Carcinoma

Start: 2011-04-30End: 2016-12-31Updated: 2017-02-09

Phase 3

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

CompletedNCT00471146

PfizerCarcinoma, Pancreatic Ductal

Start: 2007-07-31End: 2010-11-30Updated: 2012-07-16

Related Papers

Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2017-05-201 citations

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients

CPT Pharmacometrics & Systems Pharmacology2017-04-0517 citations

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

BMC Cancer2015-04-3022 citations

Overall survival and final efficacy and safety results from a Japanese phase <scp>II</scp> study of axitinib in cytokine‐refractory metastatic renal cell carcinoma

Cancer Science2014-10-0627 citations

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.

2011-03-01312 citations

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.

2008-05-29184 citations